Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SHC files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Related Party (new) — Filing references related party transactions in connection with the now-terminated Stockholders Agreement that governed sponsor rights.
Sotera Health's PE sponsors Warburg Pincus and GTCR fully exit, selling 31.8M shares at $15.17
Filed May 13, 2026 · Period ending May 11, 2026 · ~1 min read
Key Changes
-
high
Private equity sponsors Warburg Pincus and GTCR sold their entire stake of 31.8 million shares at $15.168 per share through Goldman Sachs. Sotera Health received no proceeds from this secondary offering.
Item 1.01: Underwriting Agreement view on EDGAR → -
high
The Stockholders Agreement from November 2020 terminated automatically when sponsors exited, ending their special governance rights including the ability to designate board directors. Company transitions from sponsor-controlled to fully public governance.
Item 5.03: Stockholders Agreement view on EDGAR → -
medium
Directors previously appointed by the sponsors can remain on the board until their terms expire, providing governance continuity despite the ownership change.
Item 5.03: Board Composition view on EDGAR →
Summary
Sotera Health's private equity sponsors have completed their exit from the company. Warburg Pincus and GTCR, who took the company public in 2020, sold their remaining 31.8 million shares at $15.168 per share in a secondary offering underwritten by Goldman Sachs. The company received no proceeds from the sale. This marks a significant governance transition.
The Stockholders Agreement that gave these sponsors special rights—including the power to designate board members—automatically terminated when they sold their last shares. Sotera Health is now a fully public company without sponsor control, though directors previously appointed by the sponsors may serve out their current terms.
Retail investors should watch how the board evolves and whether management strategy shifts without sponsor influence. The $15.17 sale price also provides a data point on how sophisticated sellers valued the stock. Monitor upcoming proxy statements for board composition changes and any strategic pivots now that private equity oversight has ended.
Section-by-Section Diff
Event · Item 1.02 — Termination of a Material Definitive Agreement
Stockholders' agreement dated November 19, 2020 terminated on May 13, 2026 pursuant to its terms.
Added in current filing · verify on EDGAR →
On May 13, 2026, the stockholders’ agreement (the “Stockholders Agreement”) by and among Sotera Health Company (the “Company”) and the stockholders party thereto, dated as of November 19, 2020, terminated pursuant to its terms
The Company disclosed that its Stockholders Agreement from November 2020 has terminated according to its own provisions. The filing indicates this was a scheduled termination under the agreement's terms rather than an early or unexpected event.
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
As a result of the completion of the Offering, the Sponsors will no longer own any Common Stock. The Company’s existing Stockholders Agreement terminated as a result, ending the Sponsors’ special corporate governance rights.
The Stockholders Agreement that gave Warburg Pincus and GTCR special governance rights, including the ability to designate board directors, has terminated because the sponsors no longer own any shares. This marks a transition from sponsor-controlled governance to a fully public company structure.
Event · Item 9.01 — Financial Statements and Exhibits
Item 9.01 — Financial Statements and Exhibits filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Underwriting Agreement, dated May 11, 2026, among the Company, Goldman Sachs & Co. LLC, as underwriter, and the selling stockholders named in Schedule 2 thereto.
Sotera Health entered into an underwriting agreement on May 11, 2026, with Goldman Sachs serving as underwriter for a secondary offering by existing selling stockholders. This is a secondary offering where existing shareholders are selling their shares, not the company issuing new equity. The company itself is not raising capital from this transaction.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Opinion of Cleary Gottlieb Steen & Hamilton LLP.
The company filed a legal opinion from Cleary Gottlieb Steen & Hamilton LLP, which is standard documentation for securities offerings to confirm the validity of shares being sold. This is routine procedural documentation accompanying the underwriting agreement.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 25, 2026 · How we verify